Intercurrent and autoimmune processes in type 1 diabetes mellitus

Cite item

Full Text


Aim. To estimate the prevalence of autoantibodies pathognomonic for autoimmune diseases of connective tissue and liver in patients with type 1 diabetes mellitus (DM1) and to study their clinical features in patients positive for these indicators. Subjects and methods. A total of 84 patients (39 men and 45 women) with DM1 divided into 2 groups were examined. Biochemical, immunological, and instrumental examinations were performed. Results. There was a high prevalence of markers of autoimmune diseases of connective tissue and liver in patients with DM1 and that of autoantibodies in those without its clinical symptoms or signs according to instrumental findings. Conclusion. The findings may suggest that patients with DM1 have a higher risk of concomitant autoimmune diseases with a probability of their asymptomatic course.


  1. Wägner AM, Santana Á, Hernández M, Wiebe JC, Nóvoa J, Maurici D. Predictors of associated autoimmune diseases (AAID) in families with type 1 diabetes (T1D). Results from the Type 1 Diabetes Genetics Consortium (T1DGC) Diabetes. Metab Res Rev. 2011;27(5):493-498. doi: 10.1002/dmrr.1189.
  2. Barker JM, Yu J, Yu L, Wang J, Miao D, Bao F. Autoantibody «subspecificity» in type 1 diabetes: Risk for organ-specific autoimmunity clusters in distinct groups. Diabetes Care. 2005;28(4): 850-855.
  3. Triolo TM, Armstrong TK, McFann K, Yu L, Rewers MJ, Klingensmith GJ, Eisenbarth GS, Barker JM. Additional Autoimmune Disease Found in 33% of Patients at Type 1 Diabetes Onset. Diabetes Care. 2011;34(5):1211-1213.
  4. Tsirogianni A, Pipi E, Soufleros K. Specificity of islet cell autoantibodies and coexistence with other organ specific autoantibodies in type 1 diabetes mellitus. Autoimmun Rev. 2009;8(8): 687-915.
  5. Damoiseaux J, Agmon-Levin N, Blerk MV, Chopyak V, Eriksson C, Heijnen I, Herold M, Høgåsen K, Musset L, Radice A, de Sousa MJR, Viander M, Shoenfeld Y. From ANA-screening to antigen-specificity: an EASI-survey on the daily practice in European countries. Clin Exp Rheumatol. 2014;32(4):539-646. Epub 2014 Jun 30.
  6. American College of rheumatology (ACR). Position Statement Methodology of Testing for Antinuclear Antibodies. 2009.
  7. Czaja Albert J, Freese Deborah K. Diagnosis and Treatment of Autoimmune Hepatitis. AASLD Practice Guidelines; 2012.
  8. Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16(9):1598-1619. doi: 10.1002/ibd.21219.
  9. Ramos-Casals M, Nardi N, Lagrutta M, Brito-Zerón P, Bové A, Delgado G, Cervera R, Ingelmo M, Font J. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine. 2006;85(2):95-104.
  10. Rojas-Villarraga A, Amaya-Amaya J, Rodriguez-Rodriguez А, Rube ́n D. Mantilla, Anaya JM. Introducing Polyautoimmunity: Secondary Autoimmune Diseases No Longer Exist. Autoimmune Dis. 2012;Article ID 254319. 9 pages. doi: 10.1155/2012/254319.
  11. Van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev. 2011;91:79-118.
  12. Van den Driessche A, Eenkhoorn V, Van Gaal L, De Block C. Type 1 diabetes and autoimmune polyglandular syndrome: A clinical review. Neth J Med. 2009;67(11):376-387.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies